# Thermo Fisher Scientific Inc. (TMO)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $177.52B  
**Price:** $469.63 (-0.67%)

> Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company operates through four main segments: analytical technologies, which focuses on advanced instrumentation for research and analysis; specialty diagnostic products for clinical and healthcare applications; life science solutions offering reagents and tools for biological research; and lab products and services, including contract research organization services to support scientific workflows. These offerings enable advancements in healthcare, pharmaceuticals, biotechnology, and academic research by delivering high-quality tools for discovery, development, and production processes. Thermo Fisher Scientific Inc. serves a global customer base across research institutions, pharmaceutical companies, diagnostics providers, and industrial sectors, facilitating innovation in drug development, genomics, proteomics, and clinical diagnostics. Founded in 2006 and headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. plays a pivotal role in enabling scientific breakthroughs and operational efficiency in life sciences and healthcare markets.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $44.56B | — | $7.75B | $6.70B | $17.74 |
| 2024 | $42.88B | — | $7.34B | $6.33B | $16.53 |
| 2023 | $42.86B | — | $6.86B | $6.00B | $15.45 |
| 2022 | $44.91B | — | $8.39B | — | $17.63 |
| 2021 | $39.21B | — | $10.03B | — | $19.46 |
| 2020 | $32.22B | — | $7.79B | — | $15.96 |
| 2019 | $25.54B | — | $4.59B | — | $9.17 |
| 2018 | $24.36B | — | $3.78B | — | $7.24 |
| 2017 | $20.92B | $11.94B | $2.96B | — | $5.59 |
| 2016 | $18.27B | $10.06B | $2.46B | — | $5.09 |
| 2015 | $16.96B | $9.38B | $2.34B | — | $4.92 |
| 2014 | $16.89B | $8.95B | $2.50B | — | $4.71 |
| 2013 | $13.09B | $6.78B | $1.61B | $1.27B | $3.48 |
| 2012 | $12.51B | $6.41B | $1.48B | $1.18B | $3.21 |
| 2011 | $11.56B | $5.83B | $1.25B | $1.33B | $3.46 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $110.34B | $56.94B | $53.41B | $9.85B | $39.17B |
| 2024 | $97.32B | $47.74B | $49.58B | $4.01B | $31.07B |
| 2023 | $98.73B | $51.99B | $46.73B | $8.08B | $34.73B |
| 2022 | $97.15B | $53.18B | $43.98B | $8.52B | $34.28B |
| 2021 | $95.12B | $54.33B | $40.79B | $4.48B | $34.67B |
| 2020 | $69.05B | $34.55B | $34.51B | $10.32B | $21.73B |
| 2019 | $58.38B | $28.71B | $29.68B | $2.40B | $17.75B |
| 2018 | $56.23B | $28.65B | $27.59B | $2.10B | $18.99B |
| 2017 | $56.67B | $31.26B | $25.41B | $1.33B | — |
| 2016 | $45.91B | $24.37B | $21.54B | $786M | — |
| 2015 | $40.83B | $19.48B | $21.35B | $452M | — |
| 2014 | $42.85B | $22.30B | $20.55B | $1.34B | — |
| 2013 | $31.86B | $15.01B | $16.86B | $5.83B | — |
| 2012 | $27.44B | $11.98B | $15.46B | $806M | — |
| 2011 | $26.83B | $11.80B | $15.04B | $1.02B | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $7.82B | $1.52B | $6.29B |
| 2024 | $8.67B | $1.40B | $7.27B |
| 2023 | $8.41B | $1.48B | $6.93B |
| 2022 | $9.15B | $2.24B | $6.91B |
| 2021 | $9.31B | $2.52B | $6.79B |
| 2020 | $8.29B | $1.47B | $6.82B |
| 2019 | $4.97B | $926M | $4.05B |
| 2018 | $4.54B | $758M | $3.79B |
| 2017 | $4.00B | $508M | $3.50B |
| 2016 | $3.26B | $444M | $2.81B |
| 2015 | $2.94B | $423M | $2.52B |
| 2014 | $2.62B | $428M | $2.19B |
| 2013 | $2.01B | $282M | $1.73B |
| 2012 | $2.04B | $315M | $1.72B |
| 2011 | $1.69B | $261M | $1.43B |

Source: [CompaniesByCap](https://companiesbycap.com/company/TMO)